Osteopontin derived chemotactic peptides and methods of use
AssigneeChildren's Medical Center Corporation
InventorSamy Ashkar
Life of this patent
Estimating the term…
Abstract
Novel osteopontin derived chemotactic peptides are described. The peptides (or antagonists thereof) are useful in treating conditions or diseases associated with chemotaxis.
Drawings
Claims15
A purified peptide consisting of the amino acid sequence LVLDPK (SEQ ID NO:1).
A purified peptide consisting of the amino acid sequence VLDPK (SEQ ID NO:7).
A purified peptide consisting essentially of a sequence selected from the group consisting of LVLDPK (SEQ ID NO:1), LVVDPK (SEQ ID NO:3), LVPDPK (SEQ ID NO:4), LVPDSK (SEQ ID NO:5) and LVIDPK (SEQ ID NO:6, wherein the peptide consists of between 6 and 60 amino acids, wherein the peptide has chemotactic activity.
A purified peptide comprising 60 amino acids or less and the sequence VLDPK (SEQ ID NO:7), said peptide having chemotactic activity.
A purified peptide consisting of an amino acid sequence selected from the group consisting of LVLDPK (SEQ ID NO:1), LVVDPK (SEQ ID NO:3), LVPDPK (SEQ ID NO:4), LVPDSK (SEQ ID NO:5), LVIDPK (SEQ ID NO:6) and VLDPK (SEQ ID NO:7).
A purified peptide consisting of the amino acid sequence KFHSHKDKLVLDPKSK (SEQ ID NO:2).
A purified chemotactic peptide which consists of the amino acid sequence VLDPK (SEQ ID NO:7).
08/918,189Filed 21 Aug 1997 · us provisional application
Priority
22 Aug 1996
Published
US 2002/0192208 A119 Dec 2002
Granted
3 Feb 2004
Term ended
22 Dec 2017Estimated · howhide20 years from earliest known nonprovisional domestic filing plus recorded patent term adjustment, including 123 days of adjustment. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.
From animals; from humans: cytokines; Lymphokines; Interferons
Life of this patent
Term ended 22 Dec 2017 (estimated)
Priority22 Aug 1996
Filed21 Aug 1997
Published19 Dec 2002
Granted3 Feb 2004
Term ended22 Dec 2017
Priority22 Aug 1996
Granted3 Feb 2004
Term ended22 Dec 2017
Priority claimedParent application 60/023,427
Application filedUS 08/918,189
PublishedUS 2002/0192208 A1
GrantedUS 6,686,444 B2
Term endedEstimated, includes 123 days of adjustment
USPTO file history isn’t available for this patent, so only indexed dates are shown.
Description12,378 words
Summary1,659 words
#The formation of metastases from a primary tumor is a complex temporal process that involves angiogenesis, invasion of the circulatory system by tumor cells, intravasation of the endothelium, arrest in the venous or capillary bed of the target organ, extravasation, entry into the target parenchyme and proliferation of the secondary tumor in tissue different from its tissue of origin. Throughout this process metastatic tumor cells are constantly interacting with their host tissue modulating their adhesiveness to cells and extracellular matrices, degrading matrices and migrating into interstitial stroma. These events are not unique to tumor metastasis and occur in other processes such as angiogenesis, tissue remodeling, bone remodeling and embryogenesis. Experimental studies have demonstrated that invasion involves the active locomotion of tumor cells through and into tissue barriers. The molecular mechanisms regulating such invasive tumor cell migration and subsequent implantation are poorly understood but it appears that there is organ specificity of colonization.
#Several substances that stimulate tumor cell locomotion in vitro have been described. These include factors derived from resorbing bone, liver and smooth muscle. Locomotion of tumor cells can also be induced by endogenous substances in an autocrine fashion. These factors can induce two types of directed cell locomotion: (1) chemotaxis, i.e., directed locomotion of cells up a soluble gradient; or (2) haptotaxis, i.e., migration of cells up a gradient of attached molecules.
#Bone metastases are frequently one of the first signs of disseminated disease in certain carcinomas of lung, breast, prostate, kidney or thyroid. Osteoblasts, the bone forming cells, have been shown to secrete substances that induce the chemotaxis and invasion of melanoma and breast cancer cells. One product of osteoblasts that induces the migration of several cell types and is secreted by several tumors is osteopontin.
Detailed description10,719 words
#The present invention pertains to novel osteopontin derived peptides that induce the chemotaxis of several cell types including endothelial cells, tumor cells, macrophages and osteoprogenitor cells. Antibodies against these peptides neutralizes the migration of various cell types in response to osteopontin both in vitro and in vivo.
#In accordance with this invention, an “osteopontin derived chemotactic peptide” is a peptide derived from osteopontin having chemotactic activity. Peptides of this invention include peptides comprising no more than about 60 amino acid residues and comprising at least approximately five amino acid residues in length, and preferably at least about 6-45 amino acid residues in length, and more preferably at least about 10-35 amino acid residues in length, from the C-terminal region of the osteopontin polypeptide. The term “peptides of this invention” as used herein is intended to include both peptides and analogs, e.g., agonists or antagonists, thereof. Furthermore, the peptides of the invention are not intended to include the full length osteopontin polypeptide. The peptides of the invention have chemotactic activity. Examples of the peptides of the invention include: a purified osteopontin derived chemotactic peptide comprising a sequence of the formula n-R1−R2-R3-R4-R5-R6-R7-R8−c, wherein R1 is 0, 1, 3, 5, 10, 15, 20, 25, or 27 amino acids long; R2 is Leu, Val, Met or absent; R3 is Val, Leu, Ile or Met; R4 is Leu, Val, Pro or Ile; R5 is aspartic acid or any acidic amino acid; R6 is Pro or Ser; R7 is Lys, Arg, Met or Ile; R8 is 0, 1, 3, 5, 10, 15, 20, 25 or 27 amino acids long, and wherein c indicates the carboxy terminal direction of the peptide and n indicates the amino terminal direction of the peptide; LVLDPK (SEQ ID NO:1); KFHSHKDKLVLDPKSK (SEQ ID NO:2); LVVDPK (SEQ ID NO:3); LVPDPK (SEQ ID NO:4); LVPDSK (SEQ ID NO:5); LVIDPK (SEQ ID NO:6); and VLDPK (SEQ ID NO:7).
#The term “isolated” as used herein refers to nucleic acids of the invention which are in a non-naturally occurring form. For example, isolated DNA is a nucleic acid which is one or both of: not immediately contiguous with both of the coding sequences with which it is immediately contiguous (i.e., one at the 5′ end and one at the 3′ end) in the naturally-occurring genome of the organism from which the nucleic acid is derived; or which is substantially free or free of a nucleic acid sequence with which it occurs in the organism from which the nucleic acid is derived. The term includes, for example, a recombinant DNA which is incorporated into a vector, e.g., into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other DNA sequences.